Table 4. Ovarian Cancer Types Arising from Endometriosis Transformation.
| Population (# Patients EAOC/Total in Study) | Ovarian Cancer Type in EAOC | Age (Mean ± SD) years | Reference |
|---|---|---|---|
| Quebec, BC (41/2854) | Serous 19.51% Mucinous NR Clear-Cell 21.9% Endometrioid 24.4% | OC 53.9 ± 11.4 EAOC 48.3 ± 10.8 |
(Aris 2010) |
| Belegrade, Serbia (23/210) | Serous 3.5% Mucinous NR Clear-Cell 36.8% Endometrioid 31.6% | NR | (Dzatic-Smiljkovic et al. 2011) |
| Michigan, USA (42/184) | Serous 55% Mucinous 10% Clear-Cell 21% Endometrioid 14% | OC 59 EAOC 52 |
(Kumar et al. 2011) |
| Athens, Greece (17) | Serous 5.9% Mucinous NRClear-Cell 58.8% Endometrioid 35.3% | EAOC 58 (27-76) | (Kondi-Pafiti et al. 2012) |
| Ovarian Cancer Association Consortium (738/7911) | Serous 7.1% Mucinous 6.0% Clear-Cell 20.2% Endometrioid 13.9% | OC 56.1 EAOC 56.3 |
(Pearce et al. 2012) |
| Ankara, Turkey (45/1086) | Serous 13.3% Mucinous 8.9% Clear-Cell 37.8% Endometrioid 33.3% | EAOC 55 (35-77) | (Boyraz et al. 2013) |
| Massachusetts, USA (67/134) | Serous 0% Mucinous NR Clear-Cell 38.8% Endometrioid 61.2% | OC 56.6 EAOC 51.7 |
(Davis et al. 2014) |
| Milano, Italy (27/73) | Serous NR Mucinous NRClear-Cell 76.1%Endometrioid NR | OC 58.4 ± 11.2 EAOC 51.4 ±10 |
(Scarfone et al. 2014) |
| San Juan, Puerto Rico (20/192) | Serous 2.2% Mucinous 2.7% Clear-Cell 23% Endometrioid 50% | OC 56.1 ± 14.9 EAOC 48.8 ± 11.6 |
(Acien et al. 2015) |
| Shiraz, Iran (28/110) | Serous 14.5% Mucinous 0% Clear-Cell 14.5% Endometrioid 39% | OC 50.18 ± 12.8 EAOC 49.93 ±9.36 |
(Akbarzadeh-Jahromi et al. 2015) |
OC=Ovarian Cancer, EAOC=Endometriosis Associated Ovarian Cancer, NR=not reported